Skip to main content
SpringerLink
Log in

Immune Therapy for Castration-Resistant Prostate Cancer

  • Chapter
  • First Online:
Hormone Therapy and Castration Resistance of Prostate Cancer

  • 583 Accesses

Abstract

The standard treatment for advanced metastatic prostate cancer is androgen deprivation therapy. However, for patients with castration-resistant prostate cancer (CRPC), androgen deprivation therapy is ineffective, and subsequent treatment is needed. New agents for the treatment of advanced prostate cancer, such as abiraterone and enzalutamide, have become available; however, these compounds have prolonged survival by only a few months. On the other hand, dramatic and durable treatment responses to immune therapy have been demonstrated in various cancer types. Considering these favorable clinical outcomes, immune therapy has the potential to be one of the available treatment options for patients with CRPC. Immune therapy for the management of prostate cancer consisted mainly of clinical trial investigating therapeutic cancer vaccines and immune checkpoint inhibitors, as manipulation of the immune system has emerged as a new promising strategy for cancer treatment. In this chapter, recent outcomes of these approaches are discussed in the context of future treatments for CRPC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  CAS  Google Scholar 

  2. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  CAS  Google Scholar 

  3. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

    Article  Google Scholar 

  4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

    Article  CAS  Google Scholar 

  5. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  CAS  Google Scholar 

  6. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.

    Article  CAS  Google Scholar 

  7. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, et al. Randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2015;21:3862–9.

    Article  CAS  Google Scholar 

  8. Drake CG, Quinn D, Dreicer R, Antonarakis E, Shore N, Corman J, et al. Immune response from STRIDE, a randomized, phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs. sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2015;3:145.

    Article  Google Scholar 

  9. Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elifky A, Shore ND, et al. Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone sensitive biochemically recurrent prostate cancer: a phase II randomized trial. Clin Cancer Res. 2016. https://doi.org/10.1158/1078-0432.CCR-16-1780.

  10. Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015;6:18192–205.

    Article  Google Scholar 

  11. Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2014;2:133–41.

    Article  CAS  Google Scholar 

  12. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663–74.

    Article  CAS  Google Scholar 

  13. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase I/II dose escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:947–84.

    Article  Google Scholar 

  14. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. Proceedings of American Society of Clinical Oncology Genitourinary Cancer Symposium, 2009.

    Google Scholar 

  15. Small E, Demkow T, Gerritsen W et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castration resistant prostate cancer (CRPC) [abstract 7]. Proceedings of American Society of Clinical Oncology Genitourinary Cancer Symposium, 2009.

    Google Scholar 

  16. Van den Eertwegh AJ, Verslius J, van den Berg HP, Santegoets SA, van Moorselaar RA, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ilipimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–17.

    Article  Google Scholar 

  17. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27(25):4047–54.

    Article  CAS  Google Scholar 

  18. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, et al. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3692–704.

    Article  CAS  Google Scholar 

  19. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 2010;59:1001–9.

    Article  CAS  Google Scholar 

  20. Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate. 2012;72:834–45.

    Article  CAS  Google Scholar 

  21. Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, et al. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. BMC Cancer. 2013;13:613. https://doi.org/10.1186/1471-2407-13-613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimto H, et al. A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer. Eur Urol. 2016;70:35–41.

    Article  CAS  Google Scholar 

  23. Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76:1257–70.

    Article  CAS  Google Scholar 

  24. Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. Immunol Rev. 2016;270:193–208.

    Article  CAS  Google Scholar 

  25. Slovin SF, Higano O, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostatecancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813–21.

    Article  CAS  Google Scholar 

  26. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van der Eartwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA 184-043): a multicenter, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–12.

    Article  CAS  Google Scholar 

  27. McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012;61:1137–47.

    Article  CAS  Google Scholar 

  28. Topalian SL, Hodi FS, Brahmer JR, Gettings SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Urology, Kindai University, Osaka, Japan

    Kazuhiro Yoshimura M.D., Ph.D., Takafumi Minami, Masahiro Nozawa & Hirotsugu Uemura

Authors
  1. Kazuhiro Yoshimura M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takafumi Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahiro Nozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirotsugu Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhiro Yoshimura M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yoshimura, K., Minami, T., Nozawa, M., Uemura, H. (2018). Immune Therapy for Castration-Resistant Prostate Cancer. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_41

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_41

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation